

## Curriculum Vitae

Philip B. Gorelick, MD MPH FACP  
6540 Kolmar  
Lincolnwood, Illinois 60712

847-677-5897 (Home)  
312-996-1757 (Work)

Publications:

Journal Articles

118. Gorelick PB: Presidential Symposium Address - Cerebrovascular disease in African Americans. *Stroke* 1998; 29: 2656-2664.
119. Gorelick PB, Leurgans S, Richardson D, Harris Y, Billingsley M, and the AAASPS Investigators. *J of Stroke and Cerebrovascular Diseases* 1998; 7: 1-11.
120. Gorelick PB, Mazzone T: Plasma lipids and stroke. *J Cardiovascular Risk* 1999; 6: 217-221.
121. Nyenhuis D, Gorelick PB: Vascular dementia: a contemporary review of epidemiology, diagnosis prevention and treatment. *JAGS* 1998 46: 1437-1448.
122. Gorelick PB, Born GVR, D'Agostino RB, Hanley DF, Hiatt WR, Moye L, Pepine CJ: Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel. *Stroke* 1999; 30: 1716-1721.
123. Gorelick PB, Sacco RL, Smith DB, et al: Prevention of a first stroke: a review of guidelines and a multi-disciplinary consensus statement from the National Stroke Association. *JAMA* 1999; 281: 1112-1120.
124. Gorelick PB, Erkinjuntii T, Hofman A, Rocca W, Skoog I, Winblad B: Prevention of vascular dementia. *Alzheimer's Disease and Associated Disorders* 1999; 13 (suppl 3): S131-S139.
125. Lukovits TG, Thomas K, Gorelick PB: Stroke prevention trials: How many enrollees can be expected by site? *Neurology* 1999; 52: 1101-1102.
126. Gorelick PB: Can we save the brain from the ravages of midlife cardiovascular risk factors? *Neurology* 1999; 52: 1114-1115.
127. Gorelick PB: Carotid endarterectomy: Where do we draw the line? *Stroke* 1999; 30: 1745-1750.
128. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, et al: Preventing ischemic stroke in patients with prior stroke and transient ischemic attack. A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke* 1999; 30: 1991-1994.
129. Sacco RL, Wolf PA, Gorelick PB: Risk factors and their management for stroke prevention: Outlook for 1999 and beyond. *Neurology* 1999 (Supp 4): S15-S24.



130. Writing Committee Member for Stroke Therapy Academic Industry Roundtable (STAIR): Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke* 1999; 30: 2752-2758.
131. Chaturvedi S, Lukovits TG, Chen W, Gorelick PB: Ischemia in the territory of a hypoplastic vertebrobasilar system. *Neurology* 1999; 52: 980-983.
132. Gorelick PB: Prevention of a first stroke. *Mdvista Journal of Medicine* 2000.
133. Bonner G, Gorelick PB, Prohaska T, Freels S, Theis S, Davis L: African American caregivers' preferences for life-sustaining treatment. *Journal of Ethics, Law and Aging* 1999; 5 (1): 3.
134. Gorelick PB: Neuroprotection in acute ischemic stroke: a tale of for whom the bell tolls? *Lancet* 2000; 355: 1925-1926 (commentary).
135. Quality of Care and Outcomes Research in CVD and Stroke Working Groups: Measuring and improving quality of care. A report from the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. *Stroke* 2000, 31: 1002-1012.
136. Gorelick PB: Should we be screening relatives of patients with aneurysmal subarachnoid hemorrhage for asymptomatic aneurysm? *Current Atherosclerosis Reports* 2000, 2: 89-91.
137. Bonner GJ, Darkwa OK, Gorelick PB. Autopsy recruitment program for African Americans. *Alzheimer Disease and Associated Disorders* 2000; 14(4): 202-208.
138. Oddone E, Booss J, Brass LM, Coull B, Goldstein L, Gorelick PB, et al: Acute Stroke Management in the VA: *Federal Practitioner* 2000 (Sept): pp 40-58.
139. Statement Contributor for Stroke Therapy Academic Industrial Roundtable (STAIR) II: Recommendations for clinical trial evaluation of acute stroke therapies. *Stroke* 2001; 32: 1598-1606.
140. Ruland S, Gorelick PB, Schneck M, et al: Acute stroke care in Illinois: A statewide assessment of diagnostic and treatment capabilities. *Stroke* 2002; 33: 1334-1340.
141. Ford Lynch G, Leurgans S, Raman R, Barboi A, Gorelick PB: A comparison of stroke risk factors in patients enrolled in stroke prevention trials. *J Natl Med Assoc* 2001; 93: 79-86.

142. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, et al: Primary prevention of ischemic stroke. A statement for health care professionals from the Stroke Council of the American Heart Association. *Stroke* 2001; 32: 280-299.
143. Hassaballa H, Gorelick PB, West CP, Hansen MD, Adams HP: Ischemic stroke outcome. Racial differences in the trial of danaparoid in acute stroke (TOAST). *Neurology* 2001; 57: 691-697.
144. Gorelick PB: Stroke prevention therapy beyond antithrombotics. Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. An invited review. *Stroke* 2002; 33: 862-875.
145. Messerli FH, Hanley DF, Gorelick PB: Blood pressure control in stroke patients. What should the consulting neurologist advise? *Neurology* 2002; 59: 23-25.
146. Lynch GF, Gorelick PB, Raman R, Leurgans S: A pilot survey of African American physician perceptions about clinical trials. *J Natl Med Assoc* 2001; 93 (suppl): 8S-13S.
147. Worrall B, Johnston KC, Kongable G, Hung E, Richardson D, Gorelick PB for the AAASPS investigators: Stroke risk factor profiles in African American women: an interim report from the African-American Antiplatelet Stroke Prevention Study. *Stroke* 2002; 33: 913-919.
148. Nyenhuis D, Gorelick PB, Freels S, Garron DC: Cognitive and functional decline in African Americans with VaD, AD, and stroke without dementia. *Neurology* 2002; 58: 56-61.
149. Vickrey BG, Rector TS, Wickstrom SL... Gorelick PB, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. *Stroke* 2002; 33: 901-906.
150. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. *Lancet Neurology* 2002; 1: 149-56.
151. Nyenhuis DL, Gorelick PB, Easley C, et al. The Black Seventh-Day Adventist exploratory health study. *Ethnicity and Disease Ethn Dis* 2003; 13: 208-212.

152. Freels S, Nyenhuis DL, Gorelick PB. Predictors of survival in African American patients with AD, VaD, or stroke without dementia. *Neurology* 2002; 59: 1146-1153.
153. Wattigney WA, Croft JB, Mensah GA, Alberts MJ, Shepard TJ, Gorelick PB, et al. Establishing data elements for the Paul Coverdell National Acute Stroke Registry. Part 1: Proceedings of an expert panel. *Stroke* 2003; 34: 151-156.
154. Ruland S, Raman R, Chaturvedi S, Leurgans S, Gorelick PB. Awareness, treatment and control of vascular risk factors in African Americans with stroke. *Neurology* 2003; 60: 64-68.
155. Ruland S, Gorelick PB. Are cholesterollowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor? *Current Neurology and Neuroscience Reports* 2003; 3: 21-26.
156. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. *Stroke* 2003; 34: 335-337.
157. Johnston SC, Fayad PB, Gorelick PB, et al. Prevalence and knowledge of transient ischemic attack among US adults. *Neurology* 2003; 60: 1429-1434.
158. Whittlesey CY, Gorelick PB, Raman R, et al. Are there differences in risk factor profiles and frequency of CT/MRI-based infarcts among African American patients with and without hypertension? A report from the African American Antiplatelet Stroke Prevention Study (AAASPS). *J Natl Med Assoc* 2003; 95: 423-432.
159. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients. A randomized trial. *JAMA* 2003; 289: 2947-2957.
160. O'Brien JT, Erkinjuntti T, Reisberg B... Gorelick PB, et al. Vascular cognitive impairment. *The Lancet Neurology* 2003; 2: 89-98.
161. Nguyen-Huynh MN, Fayad P, Gorelick PB, Johnson SC. Knowledge and management of transient ischemic attacks among US primary care physicians. *Neurology* 2003; 61: 1455-1456.
162. Zakarija A, Bandarenko N, Pandey DK... Gorelick PB, Bennett C. Clopidogrel-associated TTP: An update of pharmacovigilance efforts conducted by independent researchers, the pharmaceutical suppliers, and the Food and Drug Administration. *Stroke* 2004; 35: 533-538.

163. Gencheva E, Sloan M, Leurgans S, Raman R, Harris Y, Gorelick PB, for the AAASPS Investigators. Attrition and non-compliance in secondary stroke prevention trials. *Neuroepidemiology* 2004; 23: 61-66.
164. Iadecola C, Gorelick PB. Hypertension, Angiotensin and stroke: beyond blood pressure. *Stroke* 2004; 35: 348-350.
165. Bruno A, McConnell JP, Cohen SN...Gorelick PB, Bang NU. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. *Stroke* 2004; 35: 727-730.
166. Hanley D, Gorelick PB, Elliott WJ, et al. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association Work Group on Recurrent Stroke Prevention. *Journal of Stroke and Cerebrovascular Diseases* 2004; 13: 196-207.
167. Gorelick PB. TIA incidence and prevalence. The Stroke Belt perspective. *Neurology* 2004; 62 (Suppl 6): S12-S14.
168. Nyenhuis DL, Gorelick PB, Geenen EJ, Smith CA. The pattern of neuropsychological deficits in vascular cognitive impairment- no dementia (Vascular CIND). *The Clinical Neuropsychologist* 2004; 18: 41-49.
169. Gorelick PB, Ruland S. IMAGES and FAST-MAG: magnesium for acute ischemic stroke. *The Lancet Neurology* 2004; 3: 330.
170. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. *Stroke* 2004; 35 (Suppl I): 2620-2622.
171. Pedelty L, Gorelick, PB. Chronic management of blood pressure after stroke. *Hypertension* 2004; 44: 1-5.
172. Sloss EM, Wickstrom SL, McCaffrey DF, ...Gorelick PB, Dake MD, Vickrey BG. Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions. *Cerebrovas Dis* 2004; 18: 8-15.
173. Bruno A, McConnell JP, Cohen SN, ...Gorelick, PB, Bang NU. Plasma thrombosis markers following cerebral infarction in African Americans. *Thrombosis Research* 2005; 115: 73-77.
174. Pandey DK, Gorelick PB. Should statin agents be administered to all ischemic stroke patients? *Arch Neurol* 2005; 62:23-24 (editorial).

175. Gorelick PB. Cognitive vitality and the role of stroke and cardiovascular disease risk factors. *Stroke* 2005; 36: 875-879.
176. Iadecola C, Gorelick PB. The Janus face of cyclooxygenase –2 in ischemic stroke. Shifting toward downstream targets. *Stroke* 2005; 36: 182-185.
177. Ruland S, Hung E ...Gorelick PB. Impact of obesity and the metabolic syndrome on risk factors in African American stroke survivors. A report from AAASPS. *Arch Neurol* 2005; 62: 386-390.
178. Schwamm LH, Pancioli A, Acker JE ...Gorelick PB.... Recommendations for the establishment of stroke systems of care. Recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. *Stroke* 2005; 36: 690-703.
179. Radziszewska B, Hart RG, Wolf PA, D'Agostino RB, Cutler JA; Contributing Co-Authors: ...Gorelick PB.... *Neuroepidemiology* 2005; 25: 91-104.
180. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use. An update. *Stroke* 2005; 36: 1801-1807.
181. Pandey DK, Gorelick PB. Epidemiology of stroke in African Americans and Hispanic Americans. *Med Clin N Am* 2005; 89: 739-752.
182. Gorelick PB. The main outcomes of the MOSES study. *Hospital Pharmacy Europe* 2005 (Sept/Oct); 22: 60-61.
183. Wang C, Stebbins GT, Nyenhuis DL ...Gorelick PB. Longitudinal changes in white matter following ischemic stroke: a three-year follow-up study. *Neurobiology of Aging* 2005 (in press).
184. Pytel P, Cochran EJ, Bonner G ...Gorelick PB. Vascular and Alzheimer type pathology in an autopsy study of African Americans. *Neurology* 2006 (in press).

Abstracts:

56. African American Antiplatelet Stroke Prevention Study, Clinical Trials Poster Session, 24th AHA International Conference on Stroke and Cerebral Circulation, February 5, 1999, Nashville, TN.
57. Sloss EM, Wickstrom SL, McCaffrey DF, Garber S, Rector TS, Levin R, Guzy P, Gorelick PB, et al. Direct medical costs attributable to acute myocardial infarction

and ischemic stroke in cohorts with atherosclerotic conditions. *Circulation* 2001; 104: (Supp II): 798.

58. Holloway RG, Rush SR, Anderson D, Bartheson JD, Gorelick PB, et al: Quintessentials™: an innovative, online strategy to improve stroke prevention care. American Board of Specialty Societies, March 22, 2001.
59. Vickrey B, Rector T, Sloss E, Wickstrom S, Garber S, McCaffrey D, Guzy P, Gorelick PB, Levin R: Incidence of secondary stroke and myocardial infarction based on managed care administrative data. 26<sup>th</sup> International Stroke Conference, February 14-16, 2001 (platform).
60. Sloan MA, Gencheva E, Leurgans S, Harris Y, Gorelick PB: Attrition and non-compliance in secondary stroke prevention trials. A preliminary report from the AAASPS. 26<sup>th</sup> International Stroke Conference, February 14-16, 2001 (poster).
61. Chaturvedi S, Raman R, Leurgans S, Gorelick PB. Characteristics and treatment of diabetic African American stroke patients: the AAASPS experience. 27<sup>th</sup> International Stroke Conference, February 7-9, 2002 (poster).
- 62.-67. Presentations at the Second International Congress on Vascular Dementia (January 2002):
  62. Nyenhuis DL, Gorelick PB, Freels S. Cognitive and functional decline in African Americans with VAD, AD or stroke without dementia (platform).
  63. Nyenhuis DL, Freels S, Gorelick PB. Predictors of survival in African Americans with VAD, AD or stroke without dementia (platform).
  64. deToledo-Morrell L, Urresta FL... Gorelick PB. Hippocampal volume in stroke patients with and without vascular cognitive impairment (VCI) (platform).
  65. Urresta FL, Stebbins GT, ... Gorelick PB. Contralateral white matter integrity in patients with unilateral stroke (platform).
  66. Stebbins GT, Urresta FL, ... Gorelick PB. The relationship of contralateral white matter integrity to the extent of unilateral stroke (poster).
  67. Nyenhuis DL, Gorelick PB, Cochran E, et al. Cognitive decline and clinocopathological correlation in African Americans with VAD, AD or stroke without dementia (SWD) (poster).

68. Johnston SC, Fayad PB, Gorelick PB, et al. Prevalence of transient ischemic attack in the United States: results from a survey of 10,112 adults. 28<sup>th</sup> International Stroke Conference (p 170), February 13-15, 2003.
69. Askiel B, et al. Serial urinary 11- dhydrothromboxane B2 measurements in African Americans after cerebral infarction: correlation with aspirin dose and vascular events (poster). 29<sup>th</sup> International Stroke Conference. San Diego, CA, February 5-7, 2004.
70. Pandey D, ...Gorelick PB. Usefulness of a computer algorithm for the validation of stroke type in a community-wide stroke registry. 29<sup>th</sup> International Stroke Conference. San Diego, CA, February 5-7, 2004.
71. deToledo-Morrell L, Urresta FL, Stoub TR, Nyenhuis DL, Gencheva E, Freels S, Bennett DA, Gorelick PB. Hippocampal and entorhinal volume in stroke patients with and without vascular cognitive impairment (VCI) compared to elderly people with mild cognitive impairment (MCI). J Neurol Sci 2004; 226: 140.
72. Stebbins GT, Nyenhuis DL, Freels S, deToledo-Morrell L, Gencheva E, Moseley ME, Bangen KJ, Turner DA, Gabrieli JDE, Gorelick PB. A diffusion tensor imaging study of normal appearing white matter integrity in recent ischemic stroke – relationship to cognitive function. J Neurol Sci 2004; 226:147.
73. Stebbins GT, Nyenhuis DL, Freels S, deToledo-Morrell L, Gencheva E, Moseley ME, Bangen KJ, Turner DA, Gabrieli JDE, Gorelick PB. Application of Diffusion Tensor Imaging in Vascular Dementia and Vascular Cognitive Impairment. J Neurol Sci 2004; 226:147.
74. Wang C, deToledo-Morrell L, Nyenhuis DL, Gencheva E, Gorelick PB, Turner D, Moseley M, Stebbins GT. Longitudinal diffusion tensor imaging study of the Microstructural integrity of white matter in ischemic stroke patients. J Neurol Sci 2004; 226:153.
75. Sripathirathan K, Urresta F, Wang C, Stoub T, Nyenhuis DL, Freels S, Gencheva E, Gorelick PB, Turner DT, deToledo-Morrell L. Vascular cognitive impairment in stroke patients is not associated with hippocampal or entorhinal cortex atrophy. Program No. 682.2 2004 Abstract Viewer/Itinerary Planner. Washington DC: Society for Neuroscience, 2004. Online.
76. Stebbins GT, Nyenhuis DL, Fleischman DA, Bangen KJ, deToledo-Morrell L, Turner DA, Bennett DA, Gorelick PB, Gabrieli JDE. Dissociation of medial temporal lobe and thalamic volumes in mild cognitive impairment and vascular cognitive impairment. Program No. 375.7 2004 Abstract Viewer/Itinerary Planner. Washington DC: Society for Neuroscience, 2004. Online.

77. Wang C, Sripathirathan K, Nyenhuis DL, Freels S, Gencheva E, Turner DA, Gorelick PB, deToledo-Morrell L. The relation of MRI – derived normalized whole brain volume and cerebrovascular disease markers with cognitive function in ischemic stroke patients. Program No. 682.3 2004 Abstract Viewer/Itinerary Planner. Washington DC: Society for Neuroscience, 2004. Online.
78. Storteboom J, Nyenhuis DL, Gorelick PB. Assessing behavioral change following stroke: an application of the Frontal Systems Behavior Scale (FrSBe). *J Int Neuropsychol Soc* 2004; 10 S1:115.
79. Williamson J, Nyenhuis DL, Pedelty L, Byrd S, Jhaveri M, Gorelick PB. Lesion location and behavioral disinhibition: posterior fossa contributions to quantifiable behavioral change. *J Int Neuropsychol Soc* 2005; 11 S1:124.
80. Nyenhuis DL, Gencheva E, Freels S, Gorelick PB. Vascular CIND patients do not convert to dementia at a higher rate than stroke patients without baseline cognitive impairment when followed for up to three years. *J Int Neuropsychol Soc* 2005; 11 S1:189.
81. Stebbins GT, Nyenhuis DL, Fleischman DA, Bangen KA, deToledo-Morrell L, Turner DA, Bennett DA, Gorelick PB, Gabrieli JDE. Voxel Based Morphometry Gray Matter Density Study of Mild Cognitive Impairment and Vascular Cognitive Impairment – No Dementia. *J Int Neuropsychol Soc* 2005; 11 S1:189.
82. Stebbins GT, Nyenhuis DL, Wang C, Freels S, deToledo-Morrell L, Johnson J, Sripathirathan K, Gabrieli JDE, Gorelick PB. Gray matter atrophy in ischemic stroke patients with vascular cognitive impairment – no dementia. *Neurology* 2005; 64; A397.
83. Pedelty L, Nyenhuis DL, Stebbins GT, deToledo-Morrell L, Freels S, Berry-Kravis E, Byrd S, Jhaveri M, Wang C, Sripathirathan K, Gorelick PB. Risk markers for vascular CIND after stroke. *Neurology* 2005; 64; A398.
84. Chaturvedi S, ...Gorelick PB. Is left ventricular hypertrophy a predictor of recurrent vascular events in African-American patients. Presented at the AHA International Stroke Conference, February 2-4, 2005 (poster #345).

#### Letters

12. Gorelick PB, Hanley D: Clopidogrel and its use in stroke patients. *Stroke* 1998; 29: 1737.
13. Smith DB, Gorelick P: National Stroke Association Guidelines to Prevent Stroke. *JAMA* 1999; 282: 2000-2001.

14. Nyenhuis DL, Gorelick PB. Reply to Neurology 2002; 58: 56-61. Neurology 2002; 59: 475-476.

#### Books, Chapters and Reviews

24. Lukovits T, Gorelick PB: Stroke in African Americans. In: Management of Ischemic Stroke. Cohen S (ed) McGraw-Hill, New York, 2000, pp 485-495.
25. Gorelick PB, Griffith P: Late sequelae of cerebrovascular disease in African-Americans: vascular dementia. In: Stroke in Blacks, Gillum RF, Gorelick PB, Cooper ES (eds). Basel, Karger, 1999, pp 188-197.
26. Schneck MS, Chaturvedi S, Thompson D, Gorelick PB: Antiplatelet and anticoagulant therapy in stroke prevention in African Americans. In: Stroke in Blacks, Gillum RF, Gorelick PB, Cooper ES (eds). Basel, Karger, 1999, pp 167-179.
27. Gillum RF, Gorelick PB, Cooper ES (eds): Stroke in Blacks. Basel, Karger, 1999.
28. Gorelick PB: Are more subjects better in a randomized controlled trial (perspective). In: Current Review of Cerebrovascular Disease. Fisher MA, Bogousslavsky J (eds), Current Medicine 1999, pp 220-221.
29. Jensen TS, Gorelick PB: Headache associated with ischemic stroke and intracranial hematoma. In: The Headaches. Olesen J, Welch KMA, Tfelt-Hansen P (eds). Lippincott-Raven (in press).
30. Ford-Lynch G, Washington J, Gorelick PB: Lacunar stroke in black patients. Clinical presentation and detection. In: Stroke in Blacks, Gillum RF, Gorelick PB, Cooper ES (eds). Basel, Karger, 1999, pp 19-28.
31. Ford-Lynch G, Gorelick PB: Stroke in African Americans. Neurologic Clinics 2000; 19: 273-290.
32. Gorelick PB: Symptomatic carotid stenosis, endarterectomy, angioplasty and stents. Rev Soc Cardiol de Sao Paulo 1999; 4: 625-30.
33. Gorelick PB: Prevention and screening programs. In: Hachinski V, Norris JW (eds): Stroke Prevention. Oxford University Press, Oxford, 2001, pp 117-136.
34. Gorelick PB: Stroke Prevention. In: Noseworthy J (ed): Neurological Therapeutics. Principles and Practice. Martin Dunitz Publishers (The Livery House), London (in press).

35. Gorelick PB: Primary and Secondary Prevention of Stroke. In: Bogousslavsky J (ed): Drug Therapy for Stroke Prevention. Taylor and Francis Ltd, London, 2001, pp 14-34.
36. Gorelick PB: Aspirin plus extended-release dipyridamole: A new antiplatelet agent for secondary stroke prevention. NSA Stroke Clinical Updates 2000; 10:1-4.
37. Gorelick PB: Screening for intracranial aneurysms in first-degree relatives (commentary). N Engl J Med Journal Watch (Neurology) 2000; 2: 9.
38. Contributor to alcohol and Cardiovascular Diseases, Novartis Foundation Symposium 216, 1998.
39. Gorelick PB: Homocysteine in cardiovascular disease: causal or casual? N Engl J Med Journal Watch (Neurology) 2000; 2: 51-52.
40. Gorelick PB: Prevention. In: Erkinjuntii T, Gauthier S (eds): Vascular Cognitive Impairment Andover, Martin Dunitz, 2002, pgs 571-586.
41. Gorelick PB: Prevention. In: Bowler JV, Hachinski V (eds): Vascular Cognitive Impairment: Preventable Dementia. Oxford University Press, 2003; pgs. 308-320.
42. Gorelick PB (ed): Cardiovascular Disease and Stroke in Current Atherosclerosis Reports, March 2000; 2: 89-180.
43. Smith DB, Gorelick PB: Prevention of a first stroke. Cardiology Review 2001; 18(10): 35-37.
44. Gorelick PB, Sloan MA (eds): Atlas of Cerebrovascular Disease (2<sup>nd</sup> edition) 2001, Science Press Internet Services; [www.strokeatlas.com](http://www.strokeatlas.com).
45. Gorelick PB (book review): Stroke a Practical Guide to Management, 2<sup>nd</sup> edition by Warlow CP, Dennis S, van Gijn J, et al, Malden MA, Blackwell Science, 2000. Ann Neurol 2001; 557-558.
46. Gorelick PB, Alter MA (eds): Stroke Prevention. New York, Parthenon Publishers, 2002.
47. Gorelick PB, Rothbart D: Should you screen for an aneurysm in a migraineur whose mother died from a ruptured intracranial saccular aneurysm? [expert opinion]. Headache 2001; 41: 204-205.

48. Gorelick PB: Does ramipril prevent stroke and stroke-related disability? N Engl J Med Journal Watch (Neurology) 2002; 4: 49.
49. Gorelick PB. What could we accomplish by controlling stroke risk factors? Quality Perspective (Alabama Quality Assurance Foundation) May 2002.
50. Gorelick PB. An itegrated approach to stroke prevention. In: Chalmers J (ed): Clinician's Manual on Blood Pressure and Stroke Prevention (3<sup>rd</sup> Edition). SP (Science Press), London, 2002, pgs. 55-65.
51. Gorelick PB. North American perspective of antiplatelet agents. In: Barnett HJM, Bogousslavsky J, Meldrum H (eds): Ischemic Stroke: Advances in Neurology, vol 92. Lippincott Williams and Wilkins, Philadelphia, 2003, pgs 281-291.
52. Gorelick PB, Ruland SD. Stroke risk factors. In: Aminoff M, Daroff R (eds): Encyclopedia of the Neurological Sciences, Academic Press, San Diego, vol 4, 2003, pgs. 408-410.
53. Ruland SD, Gorelick PB. Lacunar infarcts. In: Aminoff M, Daroff R (eds): Encyclopedia of the Neurological Sciences, Academic Press, San Diego, vol 2, 2003, pgs 741-745.
54. Gorlelick PB. Book review of the Brain Atlas. A Visual Guide to the Human Central Nervous System, 2<sup>nd</sup> Edition by Woolsey TA, Hanaway J, Gado MH, 2003, Wiley and Sons, 249 pages. J Natl Med Assoc 2003; 95: 245.
55. Kasner SE, Gorelick PB (eds). Prevention and Treatment of Ischemic Stroke. Butterworth Heinemann, 2004.
56. Gorelick PB, Ruland S. Stroke Risk Factors. Encyclopedia of the Neurological Sciences. Elsevier Science, 2003, pp. 408-410.
57. Sacco RL, Gorelick PB. Primary prevention of ischemic stroke (chapter 38) (Noseworthy J et al eds; in press).

#### Grant Applications and Funding:

2000-2005 African American Antiplatelet Stroke Prevention Study  
 \$15.7 million  
 PI  
 Sponsor: NINDS

2000-2005 Risk Markers for Dementia After Stroke  
\$3.17 million  
PI (2000-2003; DL Nyenhuis PI 2004-2005)  
Sponsor: NIA

NIH Site Visits/Reviews:

1999 Predictors of Severity of Alzheimer's Disease (Chair)  
1999 Stroke, MI and Antiphospholipid Antibodies (Chair)  
2000 Mayo Clinic Parkinson's Disease Grant (reviewer)  
2004 NINDS T32 Review (Reviewer)

Other NIH Invitations

2001 NINDS Stroke Progress Review Group  
(Panel Co-Chair and panel member)  
2002 NINDS Stroke Disparities Meeting  
(Meeting Chair)  
2004 NINDS Primary Stroke Prevention Workshop  
(panel co-chair and panel member)

Fellows Trained:

1999-2000 Sean Ruland, DO  
2002-2003 Laura Pedelty, MD PhD

Editorships:

1990-1994 Journal of Neuroepidemiology  
(Regional Editor)  
1993-1996 Journal of Neuroepidemiology  
(Deputy Editor)

1991 Revista Neurologica Argentina  
(International Advisory Board)

1992-2000 Clinical Neuropharmacology  
(Section Editor, Cerebrovascular Disease)

1995-2004 The Journal of Mental Health and Aging  
(Associate Editor)

1997-2000 Journal of Neuroepidemiology  
(Editor-in-Chief)

1997-2002 Neurology  
(Editorial Board)

1997- Cerebrovascular Disease  
(Editorial Advisory Board)

2000 Current Controlled Trials in Cardiovascular Medicine (Editorial Board)

2000 Seminars in Stroke and Cerebrovascular Diseases (Editorial Board)

2003-present Stroke (Editorial Board)

Manuscript Reviewer:

1987, '89, '92-'97,  
'99, '00, '01, '02, Journal American Medical Association  
'03, '04

1987-1996 Stroke

1999 American Journal of Hypertension

1999, 2000 New England Journal of Medicine

1998, 2003 Journal of Neurological Sciences

1999 Cerebrovascular Diseases

1999 Journal of the National Medical Association

1988 Archives of Ophthalmology

1988-1997 Neurology

1989, 2002, 2004 Annals of Neurology

1990-1997 Journal of Neuroepidemiology

1990 Patient Care

1991-1997 Clinical Neuropharmacology

1992 ACP Journal Club

1992 Cephalgia

1993, 1995,  
1996 Journal of Clinical Epidemiology

1993-1995,  
1998 Archives of Neurology

1994, 1995,  
1997, 1998, Annals of Internal Medicine  
2000, 2003, 2004

1995 Journal Neurology

1996 Southern Medical Journal

2000 Controlled Clinical Trials. Design, Methods and Analysis

2000, 2003, 2004 Lancet

2000 Emergency Medicine

2000, 2002 Neurologist

2000 Critical Care Medicine

2002 Journal National Medical Association

2003 Lancet Neurology

2004 Mayo Clinic Proceedings

#### 1998 - 1999

1. Relationship Between Hypertension and Stroke in Persons of African Ancestry, 25th Annual Convention of the AMHE, Chicago, IL July 25, 1998.
2. Stroke Prevention, Grand Rounds, Department of Neurology, University of Wisconsin, Madison, WI, August 14, 1998.

3. Epidemiology of Stroke and Vascular Dementia, International Conference on Cerebrovascular Disease, Buenos Aires, Argentina, August 28, 1998.
4. Antiplatelet Therapy and the CAPRIE Trial, Final Results of the NASCET Study, Vascular Dementia, Hyperlipidemia, Brazilian Academy of Neurology, Sao Paulo, August 29 - September 3, 1998.
5. Cerebrovascular Disease in African Americans, Stroke Update 1998, University of Mississippi School of Medicine, Jackson, Miss, September 12, 1998.
6. Burden of Stroke Overall and in Different Ethnic Populations, 3rd Annual Meeting Advances in Stroke Management, Crete, Greece, October 4, 1998.
7. Prevention of Vascular Dementia, 3rd International Conference on Harmonization of Dementia Drug Guidelines: the Osaka Conference on Vascular Dementia 1998," Osaka, Japan, October 7-9, 1998.
8. Course Director, AAN Acute Stroke Management Workshop, Lake Forest, IL October 24, 1998.
9. Vascular Dementia, XV Peruvian Congress of Psychiatry, Lima, Peru, November 18-21, 1998.
10. Evaluation of the Stroke Prone Patient, Advances in the Prevention of Cardiovascular Disease, Raleigh, NC, December 12, 1998.
11. Stroke Risk Factors, Health Science Center for CME, St. Louis, MO, November 30, 1998.
12. Stroke Risk Factors, Preventing and Treating Ischemic Stroke: Emerging Strategies, Miami, FL, November 14, 1998.
13. Vascular Dementia, Southern Clinical Neurological Society, Curacao, January 19, 1999.
14. Consensus Conference Participant on Preclinical Assessment of Potential Stroke Therapies, Orlando, FL, March 6-7, 1999.
15. Secondary Prevention of Stroke in the Elderly, Cardiovascular Disease in Older Patients, Chicago, Illinois, December 7, 1998.

16. AAN Course 3 Pc. 001, Topics in the Neurology of Alcoholism, 51st Annual Meeting AAN, Toronto, CA, April 19, 1999.
17. AAN Course, Cerebrovascular Disease, 51st Annual Meeting AAN, Toronto, CA, April 24, 1999.

1999 - 2000

1. Racial Disparities in Stroke, 14th Annual Interdisciplinary Conference on Hypertension in Blacks, July 12, 1999, Toronto, CA
2. Carotid Endarterectomy: Where Do We Draw the Line? Joint Neurology/Neurosurgery Grand Rounds, Rush Medical Center, August 5, 1999.
3. Stroke Prevention Guidelines - The Pivotal Role of the Family Physician. September 18, 1999, Orlando, FL.
4. Management of Vascular Dementia: Satellite Symposium at the First International Congress on Vascular Dementia, Geneva, Switzerland, October 3-6, 1999.
5. Prevention of Vascular Dementia. Plenary Session, First International Congress on Vascular Dementia, Geneva, Switzerland, October 3-6, 1999.
6. Cognitive Health and Cardiovascular Disease Risk Factors. Cognitive Neurology and Alzheimer's Disease Center Seminars, Northwestern Medical School, October 14, 1999.
7. Stroke Risk Factor Management. AHA Advances in Stroke Management Seminar, St. Louis, MO, November 5, 1999.
8. New Treatments for Ischemic Stroke
  1. St. Therese Hospital, November 4, 1999
  2. West Suburban Hospital, November 17, 1999
  3. Lutheran General Hospital, November 17, 1999
9. Key Note Lecture: Stroke Epidemiology and risk factors, 12th Annual Scientific Meeting of the Hong Kong Neurological Society, December 5, 1999, Hong Kong, China.
10. Stroke in African Americans at The Epidemiology of Stroke Course, sponsored by Univ of Maryland Stroke Center, 2/12/00, New Orleans, LA.

11. Stroke Prevention, Chicago Medical Society 2000 Midwest Clinical Conference, 2/25/00.
12. Acute Stroke Treatment in Y2K, FLASHneuro Millennium Symposium, Palm Beach, FL, 2/28/00.
13. Risk Factors: Old and New, Stroke Prevention 2000 Fellows Forum, San Juan, PR, 4/8/00.
14. Primary and Secondary Stroke Prevention, 4th Annual Hot Topics in Neurology, Toledo, OH, 4/14/00.
15. Preventing Secondary Stroke, AHA Professional Stroke Conference, St. Joseph, MO, 4/29/00.
16. Stroke Prevention, Stroke 2000- A Spectrum of Care, Christiana Care, Newark, Delaware, 5/13/00.
17. Emerging Treatments for Secondary Stroke Prevention, PriMed Midwest Today, Rosemont, IL, 6/16/00.

#### 2000-2001

1. Managing Risk Factors and Preventing Stroke, 3rd Annual Neurology Update, Univ of Colorado, Aspen, CO, 8/4/00.
2. Primary Prevention in the Community, and which Antiplatelet Regimen?, North American Stroke Meeting 2000, Toronto, Canada, 9/1/00.
3. Keynote Address: Risk factors and Prevention, Stop Stroke in its Path, Michigan Dept. of Community Health, Novi, MI, 11/16/00.
4. Review Course in Neurological Surgery (COMPASS), Chicago, Illinois, February 2, 2001: Stroke Prevention in the Year 2001, Management of Hyperacute Stroke, Basic Stroke Syndromes and Diagnosis.
5. 2001 Midwest Clinical Conference, February 23, 2001: Risk Factors for Stroke.
6. Eric Corey Raps Lecturer, University of Pennsylvania, Department of Neurology, March 15, 2001: Stroke Prevention.
7. Visiting Professor, Department of Neurology, Rochester Medical Center, Rochester, NY, April 27, 2001, Stroke, Vascular Cognitive Impairment and Dementia, and Prevention Strategies.

8. Australian Association of Neurologists Annual Scientific Meeting, Adelaide, Australia, May 14-18, 2001: 1) Keynote Lecture on Prevention of Vascular Dementia; and Thalamic Syndromes.
9. AAN 53<sup>rd</sup> Annual Meeting, Philadelphia, PA, Neurology Update Course: Stroke.
10. Guest Speaker, Heart Spectrum Kick-Off Celebration for Memphis-Area AHA: Stroke in African Americans, October 13, 2001.

2001 - 2002

1. Keynote Address: Stroke: Past, Present, Future; Operation Stroke (AHA), Chicago, Illinois, February 23, 2002.
2. Guest Speaker, Stroke Risk Factors and Prevention, Chicago Neurological Society, Chicago, Illinois February 12, 2002.
3. Guest Speaker, Union Hospital Cardiovascular Symposium, February 21-22, 2002, Terre Haute, Indiana:
  - A. Risk Factors and Prevention of CVA
  - B. TIAs
  - C. Carotid Artery Disease
4. Guest Speaker, New York Academy of Medicine/National Hypertension Association/ NSA symposium on hypertension, hyperlipidemia and stroke, New York, NY: Hypertension and stroke risk: new facts, new treatment.
5. Guest Speaker, American Society of Hypertension, New York, NY, symposium on does controlling blood pressure reduce the risk of recurrent stroke and dementia? What we know about hypertension and dementia: mechanisms and interventions.
6. Guest Speaker, National Stroke Association Stroke Center Network Audioconference/Webcast: Multimodality therapy, May 22 and June 7, 2002.
7. AAN Annual Meeting 2002, Denver, Colorado, Guest Speaker:
  - A. Stroke Prevention 2002 Course on HOPE and PROGRESS trials
  - B. Cerebrovascular Disease Course on Multi-modality therapy

2002 - 2003

1. Guest Speaker, North American Stroke Meeting 2002, Mexico City, Mexico (August 16, 2002):
  - A. The importance of lifestyle in stroke prevention
  - B. The role of statin therapy and ACE-inhibitors in stroke prevention
  - C. Detection and treatment of vascular dementia
2. Guest Speaker: Keynote Address: Stroke: Past, Present and Future. Operation Stroke: Stroke: Elevating Care in the New Millennium. February 23, 2002, Chicago, Illinois.
3. Guest Speaker: Secondary Stroke Prevention of CVA: Ischemic CVA and ICH Progress Study. COSEHC's 9<sup>th</sup> National Scientific Sessions, Savannah, GA, October 18, 2002.
4. Guest Speaker: Primary Stroke Prevention. 5<sup>th</sup> Annual Vanderbilt Stroke Symposium, Nashville, TN, November 15, 2002.
5. Guest Speaker: 1<sup>o</sup> and 2<sup>o</sup> Prevention of CVA's and Vascular Dementia in the Hypertensive Patient. 7<sup>th</sup> Annual Hypertension Symposium 2002, Nashville, TN, November 15, 2002.
6. Guest Speaker: Hypertension Guidelines for Stroke Prevention. New Hypertension Guidelines: Rumors about JNC VII. Rush Medical Center, Chicago, Illinois, November 23, 2002.
7. Endowed Professorship Lecture: Insights into Preservation of Cognitive Function in Later Life: The Role of Stroke and Cardiovascular Risk Factors. Rush Medical College, Chicago, Illinois, November 26, 2002.
8. Guest Speaker: Keynote Address: Prevention of First and Recurrent Stroke: What Really Works? Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, May 30, 2003.
9. Lectures Given at AAN Annual Meeting, April 2003, Honolulu, Hawaii:
  - A. Cross Fire II on Stroke Prevention
  - B. Advances in Stroke for the New Millennium on the role for ticlopidine in stroke prevention
  - C. Stroke Prevention in 2003 on summation of recurrent and primary stroke prevention
10. Guest Speaker on Vascular MCI, Wein Center for Alzheimer's Disease and Memory Disorders, Miami, Florida, April 11-12, 2003.

11. Guest Speaker: African American Antiplatelet Stroke Prevention Study (AAASPS): Main Phase Efficacy and Safety Results. 28<sup>th</sup> International Stroke Conference, February 15, 2003, Phoenix, Arizona.

2003-2004

1. Guest Speaker: Can Vascular Cognitive Impairment Be Prevented? International Psychogeriatric Association Meeting, Chicago, IL 8/18/03.
2. Guest Speaker: Public Health Impact of Vascular Dementia and High Blood Pressure. 2003 National Public Health Stroke Summit, Denver, CO, 8/12-13/03.
3. Guest Speaker: Stroke: Risk Factors and Prevention Strategies. Chicago Neurological Society Meeting, Chicago, IL, February 28, 2004.
4. Guest Speaker: Cognitive Vitality, Chicago Medical Society Men's Health Symposium, Chicago, IL, March 6, 2004.
5. Guest Speaker: 13<sup>th</sup> European Stroke Congress, News in Stroke Prevention: Lifestyle Management, Mannheim, Germany, 5/13/04.
6. Guest Speaker: Are There Specific Antihypertensive Agents that Prevent Stroke or Is It All About Blood Pressure Control? Hypertension, Hyperlipidemia and Stroke: Utilizing Evidence to Improve Outcome. Sponsored by New York Academy of Medicine and National Hypertension Association, May 17-18, 2004.
7. Guest Speaker: Keynote Address on Challenges in Secondary Stroke Prevention, SLU Stroke Prevention Symposium, 6/12/04.
8. Guest Speaker: at 5<sup>th</sup> World Stroke Congress, Vancouver, BC, Canada:
  1. Prevention of VCI (6/26/04)
  2. Vascular Dementia: Managing Risks and Treating Cognition (6/23/04)
  3. Hypertension (6/25/04)

2004-2005

1. Guest Speaker: Advances in the Prevention of Stroke, Alexian Brothers Hospital Network, Elk Grove Village, IL, September 24, 2004.
2. Guest Speaker: Vascular Cognitive Impairment, Finch University, Department of Neurology, North Chicago, IL, 9/30/04.
3. Guest Lecture: Treatment of Hypertension in Persons with Stroke or TIA, American Society of Nephrology, St. Louis, MO, 10/27/04.

4. Guest Speaker: MATCH Study: Results and Treatment Implications. Chicago Neurological Society, Chicago, IL, 12/11/04.
5. Guest Speaker: Advances in Acute Stroke Therapies, Alexian Brothers Hospital Network, Elk Grove Village, Illinois January 10, 2005.
6. Guest Speaker: American Association of Black Cardiologists on Insights into the Primary Prevention of Stroke, Orlando, FL, March 5, 2005.
7. Keynote Speaker: Vascular Cognitive Impairment: New Insights, University of California, Irvine Comprehensive Stroke Care 2005, March 19, 2005.
8. Guest Speaker: Primary and Secondary Prevention of Stroke, American Society of Hypertension Annual Meeting, San Francisco, CA, May 17, 2005.
9. Guest Speaker: Stroke and Heart Disease in Women: What Should We Be Doing? US Mayor's Conference, US Women Mayor's Caucus, Chicago, IL, June 2005.

#### 2005-2006

1. Guest Speaker: Disparities in Stroke: Explanations and Means to Bridge the Divide, 2005 NSA Stroke Team Meeting – Southwest, Scottsdale, AZ, September 9, 2005.
2. Guest Speaker: Vascular Cognitive Impairment, Grand Rounds, University of Maryland Dept. of Neurology, September 2005, Baltimore, MD.
3. Guest Speaker: Stroke Prevention in the Elderly, 1<sup>st</sup> Annual Charles E Morris, MD Symposium: Neuropsychiatric Disorders of Aging, October 29, 2005, Deerfield, IL.
4. Guest Speaker: Lp-PLA2: A New Diagnostic Test for Assessing Stroke Risk, Stroke Belt Consortium Meeting, October 28, 2005, Orlando, FL.
5. Guest Speaker: Impact of Risk Factor Management for Stroke Prevention, Grand Rounds UAB Health Sciences Center, Tuscaloosa, Alabama, November 11, 2005.
6. Guest Speaker: Cognitive Function in the Aging Male, Chicago Men's Health Symposium, November 5, 2005, Chicago, IL.

## Other

21. Advisory Committee, WFN-Research Group in Neuroepidemiology (1998 - )
22. Committee Member, AHA 1999-2000 Scientific Meeting for Stroke and Cerebral Circulation
23. Working Group Member AHA Cardiovascular Outcomes Research Committee (1998 - 1999)
24. Chair, Writing Committee, AAN Stroke and Vascular Neurology Fellowship Curriculum (1998 - 1999).
25. Steering Committee Member, Biology of Intracranial Atherosclerosis Study (BIAS), Barney Stern, MD PI.
26. Committee Member, AAN/AHA Joint Stroke Guidelines Development Group Meeting (1998 - 1999).
27. Member, Carotid Endarterectomy Quality Measures Panel, Mark Chassin, MD PI, 1998.
28. Scientific Advisory Board, Vascular Dementia Conference 1999, Geneva, Switzerland, October 3-6, 1999.
29. Speaker, AAN Annual Meeting, Topics in the Neurology of Alcoholism - Alcohol and Stroke, April 19, 1999.
30. Speaker AAN Annual Meeting, Cerebrovascular Disease Course - Stroke Prevention, April 24, 1999.
31. Invited Speaker, The National Cerebrovascular Fellowship: Stroke Forum, New Stroke Risk Factors and Statistical Methods, Palm Beach, FL, February 16-18, 1999.
32. Member, Scientific Advisory Board, 22nd Princeton Conference on Cerebrovascular Disease, 2000.
33. Conference Cochairperson, Stroke Drug Development: Bridging the Gap from Animal Research to Human Trials, Orlando, FL, March 6-7, 1999.
34. Co-Chair, AAN Platform Session, S52, Neuroepidemiology - Stroke, April 21, 1999, Toronto, CA.
35. Abstract Reviewer, 71st Scientific Sessions, AHA.

36. Co-Chair, Quality Improvements for Stroke Care, 24th AHA International Conference on Stroke and Cerebral Circulation, February 4, 1999, Nashville, TN.
37. Co-Chair, Community/Risk Factors Session, 24th AHA International Conference on Stroke and Cerebral Circulation, February 6, 1999, Nashville, TN.
38. Member, AHA Midwest Affiliate's Stroke Planning Task Force, 1999.
39. Member, VA Stroke Quality Research Enhancement Initiative (QUERI), Acute Stroke Management Panel, Durham, NC, March 10, 1999.
40. Member, AAN Bruce Schoenberg Award Subcommittee, 1999.
41. Member, WFN-Research Group in Neuroepidemiology Executive Committee, 1999.
42. Faculty Member, AAN Quintessentials for Stroke Prevention for the Practicing Neurologist, 1999.
43. Research Advisory Committee and Research Affairs Management Committee, Rush Medical Center, 2000-
44. External Advisory Committee Member, Morehouse School of Medicine Neuroscience Institute Stroke Prevention Intervention Research Program, 2000
45. Scientific Advisory Board, 2nd International Congress on Vascular Dementia, Paphos, Cyprus, Oct. 4-7, 2001.
46. Reviewer for AHA Bugher Applications, 10/28-29/00.
47. Chair, "Prevention and etiological treatment of Alzheimer's disease and vascular dementia" session at the 2nd Paul Janssen Institute and Goteborg University Postgraduate Course, "Alzheimer's disease and vascular dementia and their interaction", Goteborg, Sweden, 9/14-16/00.
48. Chair, American Academy of Neurology Core Curriculum Task Force, 2000-2001.
49. Consultant to AHA Stroke Education and Slide Lecture Series 2000.
50. Moderator, "Telemedicine and Stroke" and "Posters II", 25th International AHA Stroke Conference.

51. Moderator, "Stroke Prevention in Minorities: Problems and Solutions", 26<sup>th</sup> International AHA Stroke Conference.
52. Member, National Stroke Association Professional Advisory Council (2000 - present).
53. Member, Planning Committee 2000-2002 Annual National Stroke Association Scientific Meeting.
54. Member, American Academy of Neurology (AAN) Acute Stroke Prevention Course Development Committee, 2002.
55. Member, Board of Directors American Heart Association Midwest Affiliate, 2001-2003.
56. Member, American Academy of Neurology Annual Meeting Subcommittee 2001-2005.
57. Course Director, Half-Day Stroke Prevention Course, American Academy of Neurology Annual Meeting, 2000-2003.
58. Co-Chair, AAN Platform Session S16: Epidemiology of Cerebrovascular Disease, May 8, 2001, Philadelphia, PA.
59. Participant, Paul Coverdell National Acute Stroke Registry Expert Panel, February 21, 2001, National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) and the Cardiovascular Health Branch, Atlanta, GA.
60. Discussant, FDA Advisory Board Meeting, March 14, 2001, Gaithersburg, MD, on prevention of vascular dementia.
61. NINDS Stroke Progress Review Group (SPRG), Co-chair Vascular Dementia Work Group and Member Clinical Trials and Prevention Work Groups, Denver, CO, July 2001.
62. Program Committee, American Stroke Association Annual Meeting, 2000-2004.
63. Moderator and speaker on secondary prevention of the brain at risk of cognitive decline, International Psychogeriatric Association Special Meeting on Vascular Burden of the Brain-New Therapeutic Directions, Nov. 28-30, 2001, Madrid, Spain.
64. Member, Rush Medical School Admissions Committee, 2001-2002.

65. Scientific Advisory Board, 23<sup>rd</sup> Princeton Conference on Cerebrovascular Disease, March 21-23, 2002, Coronado, CA.
66. Chair, NIH/NINDS Stroke Disparities Conference, Bethesda, MD, November 6-8, 2002.
67. Member, National Stroke Association, Task Force on educational materials and outreach activities for diverse, at-risk populations, 2002 (Stroke Disparities Task Force).
68. Moderator, 27<sup>th</sup> International Conference on Stroke (AHA), session on prevention and treatment of hypertension, February 7, 2002.
69. Member, Medical Advisory Board, The Hazel K. Goddess Fund for Stroke Research in Women, 2002-present.
70. Member, International Advisory Committee, World Stroke Congress 2004.
71. Member, Committee for Subspecialty Certification and Recertification in Vascular Neurology of the American Board of Psychiatry and Neurology, 2003-present.
72. Member, Expert Panel A: Policy and Programs, US Department of Health and Human Services. A Public Health Action Plan to Prevent Heart Disease and Stroke. Atlanta, GA: US DHHS, Centers for Disease Control and Prevention; 2003.
73. Co-chair, abstract session: Cerebrovascular Disease: Prevention and Acute Therapy, AAN Annual Meeting, April 2, 2003, Honolulu, Hawaii.
74. Moderator, Acute Stroke: Principles of Modern Management Course, AAN, September 21, 2002, Chicago, Illinois.
75. Member, Fair Hearing Panel, for AAN Grievance Committee, 2002.
76. Member, Planning Committee for AHA/ASA 2003 Emerging Science Satellite Broadcast, March 26, 2003.
77. Co-Chair, AHA Abstract session: Minorities in Recently Completed and Ongoing Stroke Studies, November 17, 2002, Chicago, Illinois.
78. Moderator, Vascular Cognitive Impairment (VCI): Advances and Challenges, 28<sup>th</sup> International Stroke Conference, February 14, 2003, Phoenix, AZ.

79. Scientific Program Committee Member, 24<sup>th</sup> Princeton Conference, Baltimore, MD, April 2-4, 2004.
80. Invited Speaker, 24<sup>th</sup> Princeton Conference, April 2-4, 2004, on Risk Factors for VaD and AD.
81. Moderator, 29<sup>th</sup> International Stroke Conference for session on Assessing a Population at High Risk for Stroke: Analysis of Important Observations and Outcomes in AAASPS, February 5-7, 2004.
82. Member, Executive Committee of the Medical Staff, University of Illinois Hospital, 2004 to 2007.
83. Member, AHA Council on Epidemiology and Prevention Stroke Statistics Committee, 2004.
84. Member, AHA Expert Panel on Population and Prevention Science, 2004.
85. Member, International Coordinating Committee VasCog Society 2003.
86. Member, International Advisory Committee, 5<sup>th</sup> World Stroke Congress.
87. Member, Scientific Program Committee, American Society of Hypertension 2005-2006 Annual Scientific Meeting.
88. Co-Chair, Program Committee, 30<sup>th</sup> and 31<sup>st</sup> AHA/ASA International Stroke Conference.
89. Course Director, AAN Annual Meeting Course 5TP.001, Stroke Therapy, 4/28/04.
90. Course Director, AAN Annual Meeting, Case Studies in Stroke, 2005-2006.
91. Member, Duke Stroke Policy Model Advisory Committee 2005.
92. Member State of Illinois Governor's Stroke Task Force, 2005-2006.
93. Member, American Stroke Association Advisory Committee 2005.

#### Special Awards

1. National Stroke Association Visionary in Practice Society 2000
2. Deborah R. and Edgar D. Jannotta Endowed Professorship (2001-12/ 7/ 03)

3. Fellow, American Heart Association and the Stroke Council (2001)
4. Castle Connolly Medical Ltd., Top Doctors: Chicago Metro Area (2001)
5. John S. Garvin Professor of Neurology (12/ 8 / 03 - present).
6. William M. Feinberg Award for Excellence in Clinical Stroke (AHA/ASA) 2004.
7. Fellowship Institute of Medicine Chicago 2004.
8. Member, Board of Directors, National Stroke Association (2005).
9. Henry JM Barnett Lectureship 2005, Canadian Stroke Network, Ottawa Canada, April 1, 2005.
10. Daniel C. Gainey Named Visiting Professorship in Stroke and Related Diseases, Mayo Clinic, May 2, 2005.

#### Additional Academic Appointments

1. Professor of Neurosurgery, Rush Medical College (conjoint), May 2001-12/ 7/03.